Relief Therapeutics announces supply deals while awaiting COVID-19 trial data

Relief Therapeutics announces supply deals while awaiting COVID-19 trial data

Relief Therapeutics announces supply deals while awaiting COVID-19 trial data

FILE PHOTO: An illustration, created at the Centers for Disease Control and Prevention (CDC), depicts the 2019 Novel Coronavirus

More

ZURICH (Reuters) - Switzerland's Relief Therapeutics and U.S. partner NeuroRx said on Wednesday they struck deals with Bachem and Nephron Pharmaceuticals to supply and make a 50-year-old drug, aviptadil, that is in clinical trials against COVID-19.

Relief and NeuroRx said the pact with Switzerland's Bachem, to supply peptides, and U.S. generics maker Nephron, to manufacture aviptadil, also being called RLF-100 by the companies, is aimed at having supplies sufficient to treat 1 million patients, should the drug prove effective in the studies.

sonos sonos One (Gen 2) - Voice Controlled Smart Speaker with Amazon Alexa Built-in - Black read more

(This story has been refiled to correct date to September 30)

(Reporting by John Miller; Editing by Michael Shields)

sonos sonos One (Gen 2) - Voice Controlled Smart Speaker with Amazon Alexa Built-in - Black read more

all right reserved for yahoo news

PREV Driver in his 20s arrested for attempted murder after car crash in south London ...
NEXT Troubled girl, 16, takes her own life on school grounds